5/4/26: The United States Supreme Court has ordered that "the May 1, 2026 order of the United States Court of Appeals for the Fifth Circuit" is "hereby administratively stayed until 5 p.m. (EDT) on Monday, May 11, 2026." This stay temporarily once again allows dispensing of abortion pills by mail.

Justice Samuel Alito, who wrote the order, added, "It is further ordered that a response to the application be filed on or before Thursday, May 7, 2026, by 5 p.m."

Key Takeaways:

• The U.S. Supreme Court issued a temporary administrative stay (pause) on a ruling from the Fifth Circuit Court of Appeals; this means that mail-order dispensing of the abortion pill has been temporarily restored. The stay will last one week, until May 11.

• The Fifth Circuit ruling was based on a lawsuit brought by the State of Louisiana, seeking to undo the FDA's 2023 changes to the abortion pill safety protocols (REMS), which allowed mail-order and pharmacy dispensing of the abortion pill without any in-person visits.

• Those safety protocol changes, according to the Fifth Circuit, were "based on flawed or nonexistent data" and resulted large Medicaid costs for the state, after women experienced significant adverse events from the drug.

The Background:

In October of last year, the State of Louisiana filed a lawsuit seeking to end the Food and Drug Administration's (FDA) 2023 decision to alter its safety protocol on the abortion pill (known as REMS), which allowed the abortion drug mifepristone (200mg)/Mifeprex to be permanently dispensed by mail and in pharmacies.

Prior to the Fifth Circuit's decision, Trump's FDA asked the courts in January to "stay judicial review" until the FDA completed its own review of the drug, which it claimed could be done in less than a year.

A stay in the lawsuit was approved on April 6, pending the completion of the FDA's promised safety review of the drug. It was expected to be completed a year or possibly 'sooner.' However, the State of Louisiana quickly filed an appeal on April 17, 2026.

The Fifth Circuit judges ruled last week in the Louisiana lawsuit that:

• "FDA’s justifications for remotely dispensing mifepristone were based on flawed or nonexistent data." 

• "The new regulation had resulted in numerous illegal abortions in Louisiana and in Louisiana paying thousands in Medicaid bills for women harmed by mifepristone."

This ruling paused abortion pill dispensing by mail.

Immediately, some abortion proponents vowed to continue dispensing the drugs by mail in defiance of the Appeals Court decision.

On May 2, 2026, abortion pill manufacturer Danco Laboratories, on behalf of all defendants in the case (which included the FDA and the generic pill maker GenBioPro), filed an emergency application before the Supreme Court.

Then, on May 4 the Supreme Court responded and temporarily halted the pause on abortion pill dispensing by mail, pending further review.

According to SCOTUS Blog:

In a brief order on Monday morning, Justice Samuel Alito, who handles emergency requests from the 5th Circuit, issued an administrative stay putting the 5th Circuit’s order on hold and temporarily restoring access to mifepristone by mail while the justices consider the drug companies’ request, and instructed the FDA and Louisiana to respond by 5 p.m. EDT on Thursday, May 7. The administrative stay expires on Monday, May 11, at 5 p.m. EDT.

... Danco argued that the order “injects immediate confusion and upheaval into highly time-sensitive medical decisions,” while GenBioPro said that the order “has unleashed regulatory chaos.”

...The drug companies also ask the court to issue a short-term order, known as an administrative stay, that would put the 5th Circuit’s ruling on hold while the justices consider their request. On Monday, Alito granted that request.

The Clarification:

Following the SCOTUS decision, Alliance Defending Freedom, which represents the State of Louisiana and co-Plaintiff Rosalie Markezich (a victim of coerced abortion), wrote on X:

On Friday, the Fifth Circuit GRANTED our request to reinstate the in-person dispensing requirement for the abortion drug mifepristone during our appeal. Praise God, that safeguard was in place all weekend... for the first time since 2021.

Today, the U.S. Supreme Court issued a 7-day administrative stay while Danco and GenBioPro appeal that victory. To be clear:

This is NOT a reversal of Friday's decision.

Rather, it's the run-of-the-mill pause that the Justices typically use to consider the issues raised in an emergency application. We- with @AGLizMurrill-will respond by Thursday.

The stay will expire on Monday.

We respect the Court's desire to have time to consider the issues and will continue our fight to uphold this victory that protects women and babies across the country from FDA's unlawful and destructive mail-order abortion-drug scheme.

The Bottom Line:

Attorney Mike Seibel, who frequently handles abortion malpractice cases, told Live Action News this is a "temporary pause until there can be a full briefing on the issue," adding, "All hope is not lost; pro-lifers should pray hard."

Justice Samuel Alito, who wrote the order, added, "It is further ordered that a response to the application be filed on or before Thursday, May 7, 2026, by 5 p.m."

Key Takeaways:

• The U.S. Supreme Court issued a temporary administrative stay (pause) on a ruling from the Fifth Circuit Court of Appeals; this means that mail-order dispensing of the abortion pill has been temporarily restored. The stay will last one week, until May 11.

• The Fifth Circuit ruling was based on a lawsuit brought by the State of Louisiana, seeking to undo the FDA's 2023 changes to the abortion pill safety protocols (REMS), which allowed mail-order and pharmacy dispensing of the abortion pill without any in-person visits.

• Those safety protocol changes, according to the Fifth Circuit, were "based on flawed or nonexistent data" and resulted large Medicaid costs for the state, after women experienced significant adverse events from the drug.

The Background:

In October of last year, the State of Louisiana filed a lawsuit seeking to end the Food and Drug Administration's (FDA) 2023 decision to alter its safety protocol on the abortion pill (known as REMS), which allowed the abortion drug mifepristone (200mg)/Mifeprex to be permanently dispensed by mail and in pharmacies.

Prior to the Fifth Circuit's decision, Trump's FDA asked the courts in January to "stay judicial review" until the FDA completed its own review of the drug, which it claimed could be done in less than a year.

A stay in the lawsuit was approved on April 6, pending the completion of the FDA's promised safety review of the drug. It was expected to be completed a year or possibly 'sooner.' However, the State of Louisiana quickly filed an appeal on April 17, 2026.

The Fifth Circuit judges ruled last week in the Louisiana lawsuit that:

• "FDA’s justifications for remotely dispensing mifepristone were based on flawed or nonexistent data." 

• "The new regulation had resulted in numerous illegal abortions in Louisiana and in Louisiana paying thousands in Medicaid bills for women harmed by mifepristone."

This ruling paused abortion pill dispensing by mail.

Immediately, some abortion proponents vowed to continue dispensing the drugs by mail in defiance of the Appeals Court decision.

On May 2, 2026, abortion pill manufacturer Danco Laboratories, on behalf of all defendants in the case (which included the FDA and the generic pill maker GenBioPro), filed an emergency application before the Supreme Court.

Then, on May 4 the Supreme Court responded and temporarily halted the pause on abortion pill dispensing by mail, pending further review.

According to SCOTUS Blog:

In a brief order on Monday morning, Justice Samuel Alito, who handles emergency requests from the 5th Circuit, issued an administrative stay putting the 5th Circuit’s order on hold and temporarily restoring access to mifepristone by mail while the justices consider the drug companies’ request, and instructed the FDA and Louisiana to respond by 5 p.m. EDT on Thursday, May 7. The administrative stay expires on Monday, May 11, at 5 p.m. EDT.

... Danco argued that the order “injects immediate confusion and upheaval into highly time-sensitive medical decisions,” while GenBioPro said that the order “has unleashed regulatory chaos.”

...The drug companies also ask the court to issue a short-term order, known as an administrative stay, that would put the 5th Circuit’s ruling on hold while the justices consider their request. On Monday, Alito granted that request.

The Clarification:

Following the SCOTUS decision, Alliance Defending Freedom, which represents the State of Louisiana and co-Plaintiff Rosalie Markezich (a victim of coerced abortion), wrote on X:

On Friday, the Fifth Circuit GRANTED our request to reinstate the in-person dispensing requirement for the abortion drug mifepristone during our appeal. Praise God, that safeguard was in place all weekend... for the first time since 2021.

Today, the U.S. Supreme Court issued a 7-day administrative stay while Danco and GenBioPro appeal that victory. To be clear:

This is NOT a reversal of Friday's decision.

Rather, it's the run-of-the-mill pause that the Justices typically use to consider the issues raised in an emergency application. We- with @AGLizMurrill-will respond by Thursday.

The stay will expire on Monday.

We respect the Court's desire to have time to consider the issues and will continue our fight to uphold this victory that protects women and babies across the country from FDA's unlawful and destructive mail-order abortion-drug scheme.

The Bottom Line:

Attorney Mike Seibel, who frequently handles abortion malpractice cases, told Live Action News this is a "temporary pause until there can be a full briefing on the issue," adding, "All hope is not lost; pro-lifers should pray hard."